Canada pharmaceuticals imports are currently increasing, upward of 68% and $17.6 billion in 2017. Simultaneously, the number of generic drug shortages each year is rising, indicating both a lack of market flexibility as well as a lack of sourcing control.
The production cost for generic pharmaceuticals is mainly controlled by the efficiency of manufacturing (~70% of the total cost). The traditional means of producing pharmaceuticals is batch manufacturing, where a series of large tank reactors are used to perform individual manufacturing steps. Added to the high labor costs of this approach, it is exceedingly wasteful, producing up to 200 kg waste/kg product. An alternative is continuous flow manufacturing, where highly sustainable, compact flow reactors are linked to create an assembly line of chemical production. This FDA-recommended method of manufacturing leads to a significant decrease in cost, increases in productquality and sustainability.
Utilizing patented technology and knowhow, FluxPharm Canada will produce generic small molecule pharmaceuticals in a highly scalable, modular, and systematic manner using continuous flow manufacturing. FluxPharm Canada’s R&D will develop additional processes for high need and high volume medicines for both large-scale and just-in-time production, addressing both critical needs of the Canadian and global markets, at significantly cheaper prices than current market values.
FluxPharm Canada also addresses the rapidly rising need of a skilled workforce in continuous manufacturing through training programs, where workers gain the skills required for this disruptive technology in both R&D and GMP simulated, operational manufacturing